| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/13/2001 | WO2001065911A2 Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| 09/13/2001 | WO2001045712A8 Combinations of medicaments for treating viral diseases |
| 09/13/2001 | WO2001029178A3 Epo primary response gene 1, eprg1 |
| 09/13/2001 | WO2001028576A3 NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY |
| 09/13/2001 | WO2001026635A3 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 09/13/2001 | WO2001019542A8 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 09/13/2001 | WO2001018046A3 Ovarian tumor sequences and methods of use therefor |
| 09/13/2001 | WO2001017536A3 Novel autogenous vaccines used to obtain an immune tolerance |
| 09/13/2001 | WO2001016288A3 Dna encoding the human serine protease c-e |
| 09/13/2001 | WO2001016285A3 Novel proteases and variants thereof |
| 09/13/2001 | WO2001016180A3 Cd40 agonist compositions and methods of use |
| 09/13/2001 | WO2001015733A3 Compositions for treating autoimmune disease containing a compounds which regulates icam-lfa-1 interaction and a compounds which regulates cd40-cd40 ligand interaction |
| 09/13/2001 | WO2001015671A3 Flushable disposable polymeric products |
| 09/13/2001 | WO2001009169A3 Cysteine protease inhibitors |
| 09/13/2001 | WO2001009000B1 A device for spray dispensing a composition for topical application comprising vitamin e and essential fatty acids |
| 09/13/2001 | WO2001005480A3 Chemokine binding protein of gammaherpesvirus 68 and methods of use therefor |
| 09/13/2001 | WO2000063370A3 Nucleic acids coding for novel truncated cart proteins, corresponding truncated cart polypeptides and their use for therapeutic and diagnostic purposes |
| 09/13/2001 | WO2000062795A3 UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS |
| 09/13/2001 | WO2000052148A9 Substances for controlling fertility |
| 09/13/2001 | WO2000034780A8 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3? |
| 09/13/2001 | WO1997042968A3 Administration of histamine for therapeutic purposes |
| 09/13/2001 | WO1996030521A3 Infectious dna clone of the tick-borne encephalitis (tbe) virus; recombinant vaccine derived from the said clone and production of the said vaccine; and a pharmaceutical product containing a replicable nucleic acid |
| 09/13/2001 | US20010021772 Vascular endothelial growth factor |
| 09/13/2001 | US20010021769 Cell culture product |
| 09/13/2001 | US20010021767 Gastrointestinal disorders |
| 09/13/2001 | US20010021718 Antiscarring agent |
| 09/13/2001 | US20010021713 Thromboresistant materials incorporating pyrazinone protease inhibitors |
| 09/13/2001 | US20010021702 Newly identified polypeptides and polynucleotides that encode them; used in identifying compounds which may be agonists, antagonists and/or inhbitors which are can be useful in therapy |
| 09/13/2001 | US20010021701 Contacting the ductal epithelium of the exocrine gland with epithelium destroying agents such as ethanol and vaccinia virus |
| 09/13/2001 | US20010021700 Vectors, host cells, antibodies, and recombinant and synthetic methods for producing polynucleotides and the polypeptides they encode |
| 09/13/2001 | US20010021699 Therapeutic and drug screening methods for the treatment and prevention of neuronal disease |
| 09/13/2001 | US20010021698 Methods and kits for removing, treating, or preventing lice with driable pedicul ostatic agents |
| 09/13/2001 | US20010021697 Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components |
| 09/13/2001 | US20010021696 Administering hormonally inactive insulin or analogue; selectively inhibits beta-cell destructive immune responses without inducing insulin inherent side effects |
| 09/13/2001 | US20010021695 Administering neurotoxins of botulinum toxin types in an amount to control the duration of therapeutic activity |
| 09/13/2001 | US20010021694 Treating bulimia and eating disorders, stimulating cholecystokinin, protein powder with glycomacropeptide or casein, fatty acid, fiber |
| 09/13/2001 | US20010021526 Immortal rho degrees cell line; undifferentiated cells for drug screening; alzheimers, huntington's disease, myoclonic epilepsy lactic acidosis and stroke (MELAS); myoclonic epilepsy ragged red fiber (MERRF) |
| 09/13/2001 | US20010021517 An isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with macrophase migration inhibiatory factor (MIF) gene selected from dirofilaria immitis MIF gene and Onchocerca volvulus MIF gene |
| 09/13/2001 | US20010021516 An isolated nucleic acid molecule comprising a polynucleotide having nucleotide sequence atleast 95% identical to a sequence selected from a nucleotide sequence encoding a TRID polypeptide having specific amino acid sequence |
| 09/13/2001 | US20010021512 Microsporidian polar tube proteins, nucleic acids coding for these proteins and their applications |
| 09/13/2001 | US20010021509 Conducting the identification of agonist or antagonist in the presence of labeled or unlabeled diadenosine hexaphosphate, diadenosine pentaphosphate and deoxyuridine diphosphate; HNEAA81 polypeptide with specific amino acid sequence |
| 09/13/2001 | US20010021507 Renal nuclear matrix protein able to differentiate cancerous renal cell from normal renal cells; useful for diagnosis and producing treatment for cell proliferative disorders of the kidney |
| 09/13/2001 | US20010021399 Administering lectin |
| 09/13/2001 | US20010021397 Solvent extraction from yeast |
| 09/13/2001 | US20010021395 Mixture of nucleic acid and anticancer agent |
| 09/13/2001 | US20010021393 Antibodies from eggs immunized with urease of Helicobacter |
| 09/13/2001 | US20010021388 Cyclization of a triether with a diamine compound |
| 09/13/2001 | US20010021383 Antibodies for diagnosis, therapy |
| 09/13/2001 | US20010021382 Monoclonal antibodies |
| 09/13/2001 | US20010021380 Soluble tumor necrosis factor receptor treatment of medical disorders |
| 09/13/2001 | US20010021379 Platelet-activating factor acetylhydrolase |
| 09/13/2001 | DE10010113A1 Isolation of collagen by extraction from sponge, giving product having cyclooxygenase inhibiting activity, useful for treating inflammatory diseases such as arthritis or skin inflammation |
| 09/13/2001 | CA2723031A1 Polypeptides having neutrophil stimulating activity |
| 09/13/2001 | CA2440679A1 Sphingomyelinase enzymes and uses relating thereto |
| 09/13/2001 | CA2413919A1 Methods using phytol to improve the appearance of skin and compositions for such methods |
| 09/13/2001 | CA2402896A1 Polypeptide inducing apoptosis |
| 09/13/2001 | CA2402602A1 Polynucleotides which are of nature b2/d+ a- and which are isolated from e. coli, and biological uses of these polynucleotides and of their polypeptides |
| 09/13/2001 | CA2402509A1 Methods and kits for locally administering an active agent to an interstitial space of a host |
| 09/13/2001 | CA2402311A1 Cryptococcal mannoproteins or equivalents thereof for use in modulating neutrophil migration |
| 09/13/2001 | CA2402211A1 Phosphatidyl serine receptors and uses thereof |
| 09/13/2001 | CA2402024A1 Hiv immune adjuvant therapy |
| 09/13/2001 | CA2401946A1 Rfrp-containing prolactin secretion regulatory agent |
| 09/13/2001 | CA2401708A1 Enzymes involved in triterpene synthesis |
| 09/13/2001 | CA2401549A1 G-protein coupled receptor related polypeptides |
| 09/13/2001 | CA2401525A1 Gamma-secretase inhibitors |
| 09/13/2001 | CA2401454A1 G-protein coupled receptors |
| 09/13/2001 | CA2401398A1 Dna encoding human acid-sensing ion channel bnac4 (asic4) |
| 09/13/2001 | CA2401327A1 Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use |
| 09/13/2001 | CA2401239A1 Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| 09/13/2001 | CA2400711A1 Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase |
| 09/13/2001 | CA2400628A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | CA2400415A1 Nucleic acid sensor molecules |
| 09/13/2001 | CA2400410A1 Antimicrobial compounds and formulations |
| 09/13/2001 | CA2399943A1 Immune system-related polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399921A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399913A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/12/2001 | EP1132472A1 Novel protein and utilization thereof |
| 09/12/2001 | EP1132471A2 TNF-binding proteins |
| 09/12/2001 | EP1132469A2 Methods for separating nucleic acids from Protein-nucleic acids complexes |
| 09/12/2001 | EP1132406A1 Inhibitor of metalocarboxypeptidases as fibrinolytic agent |
| 09/12/2001 | EP1132404A2 Acylated insulin |
| 09/12/2001 | EP1132403A1 Tgf g beta1 inhibitor peptides |
| 09/12/2001 | EP1132402A1 Peptide fragments having cell death inhibitory activity |
| 09/12/2001 | EP1132399A1 Mannoproteins or equivalents thereof for use in modulating neutrophil migration |
| 09/12/2001 | EP1132396A1 Physiologically active peptides |
| 09/12/2001 | EP1132395A2 Process for the preparation of a pharmacologically active peptide |
| 09/12/2001 | EP1132394A1 Stable analogs of bioactive peptides containing disulfide linkages |
| 09/12/2001 | EP1132098A1 Gene therapy for cerebrovascular disorders |
| 09/12/2001 | EP1132097A2 Cellular and serum protein anchors and conjugates |
| 09/12/2001 | EP1132091A1 Treatment for diabetes |
| 09/12/2001 | EP1132082A1 Use of substances capable of blocking the production of glutamate for treating tension-type headache |
| 09/12/2001 | EP1131633A2 Hiv-specific t-cell induction |
| 09/12/2001 | EP1131467A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 09/12/2001 | EP1131465A1 Antisense modulation of interleukin-15 expression |
| 09/12/2001 | EP1131461A1 N-terminally truncated her-2/neu protein as a cancer prognostic indicator |
| 09/12/2001 | EP1131458A1 Viral vectors with late transgene expression |
| 09/12/2001 | EP1131457A1 Systemic viral/ligand gene delivery system and gene therapy |
| 09/12/2001 | EP1131448A2 Producing antimicrobial cationic peptides as fusion proteins |
| 09/12/2001 | EP1131446A1 Coffea arabica mannanase |
| 09/12/2001 | EP1131445A1 Human phospholipases |